Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

Fig. 4

Induction of neutralizing antibodies by ECV19. A Anti-Spike (S) IgG titers and B FRNT neutralization of SARS-CoV-2 of serum sampled from participants in the indicated groups at the indicated time point. N = 27 for placebo, 96 for low-dose ECV19 and 100 for high-dose ECV19. Bars show geometric mean values within groups. Indicated **** and ** correspond to p values of < 0.0001 and < 0.01, respectively

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us